Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00827099 · ClinicalTrials.gov registry record · Phase 2
Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer
A Phase 2 study, sponsored by Northside Hospital.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT00827099 is a Phase 2 study that was terminated before completion, run by Northside Hospital. The registered enrollment target is 5 participants.
The verdict
NCT00827099, a Phase 2 study, was terminated before completion, sponsored by Northside Hospital.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
RATIONALE: Giving low doses of chemotherapy before a donor umbilical cord blood transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving tacrolimus and mycophenolate mofetil after the transplant may stop this from happening. PURPOSE: This phase II trial is studying how well giving umbilical cord blood transplant together with fludarabine, melphalan, and antithymocyte globulin works in treating patients with hematologic cancer.
Interventions
- DRUG Melphalan
- DRUG fludarabine phosphate
- DRUG tacrolimus
- BIOLOGICAL anti-thymocyte globulin
- DRUG mycophenolate mofetil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2006-06 |
| Est. Completion | 2009-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00827099
The ClinicalTrials.gov registry entry for NCT00827099 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northside Hospital, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Melphalan is the first listed.
NCT00827099 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00827099 about?
NCT00827099 is a clinical study titled "Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer". RATIONALE: Giving low doses of chemotherapy before a donor umbilical cord blood transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any rem...
What is the current status of trial NCT00827099?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2006-06. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00827099?
The interventions under investigation include: Melphalan (DRUG), fludarabine phosphate (DRUG), tacrolimus (DRUG), anti-thymocyte globulin (BIOLOGICAL), mycophenolate mofetil (DRUG).
Who is sponsoring clinical trial NCT00827099?
This trial is sponsored by Northside Hospital, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.